Page 114 - 《中国药房》2026年8期

·循证药学·

复方谷氨酰胺肠溶胶囊防治恶性肿瘤患者放化疗相关肠道功能
紊乱疗效的系统评价
Δ

#
＊
陈俞先 ，邹 丹，胡巧织（四川大学华西医院药剂科，成都 610041）
中图分类号 R975 文献标志码 A 文章编号 1001-0408（2026）08-1068-06
DOI 10.6039/j.issn.1001-0408.2026.08.17

摘 要 目的 评价复方谷氨酰胺肠溶胶囊治疗和预防恶性肿瘤患者放化疗相关肠道功能紊乱的疗效。方法 检索 PubMed、
Embase、中国知网、万方数据库，收集复方谷氨酰胺肠溶胶囊（试验组）联合或不联合其他治疗对比其他治疗或空白对照（对照组）的
随机对照研究（RCT）及队列研究，检索时限为建库至2025年11月19日。经文献筛选、资料提取及质量评价后，采用RevMan 5.4软
件进行Meta分析。结果 共纳入23项文献，共计2 014例患者。Meta分析结果显示，试验组患者的治疗有效率显著高于对照组，总
体、中重度放化疗相关肠道功能紊乱发生率和生活质量评分、白细胞介素6水平均显著低于对照组（P＜0.05）；两组患者的卡氏功能
状态评分改善率、肿瘤坏死因子α水平比较，差异均无统计学意义（P＞0.05）。按对照组用药方案不同进行亚组分析的结果显示，治
疗用药时，无论对照组患者使用空白对照还是阳性对照，试验组患者的治疗有效率均显著高于对照组（P＜0.05）；预防用药时，与对
照组中使用空白对照的患者比较，试验组患者的总体及中重度放化疗相关肠道功能紊乱发生率均显著降低（P＜0.05），而试验组与
对照组中使用阳性对照患者的总体及中重度放化疗相关肠道功能紊乱发生率比较，差异均无统计学意义（P＞0.05）。结论 复方谷
氨酰胺肠溶胶囊能有效治疗和预防恶性肿瘤患者放化疗相关肠道功能紊乱，改善患者生活质量，减轻炎症反应。
关键词 复方谷氨酰胺肠溶胶囊；肠道功能紊乱；恶性肿瘤；放疗；化疗；Meta分析；疗效

Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and
chemotherapy-related intestinal dysfunction in patients with malignant tumors： a systematic review
CHEN Yuxian，ZOU Dan，HU Qiaozhi（Dept. of Pharmacy， West China Hospital of Sichuan University，
Chengdu 610041， China）

ABSTRACT OBJECTIVE To evaluate the efficacy of Compound glutamine enteric-coated capsules in the treatment and
prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors. METHODS
PubMed， Embase， CNKI， and Wanfang data were searched to collect randomized controlled trial （RCT） and cohort studies
comparing Compound glutamine enteric-coated capsules （experimental group） with or without other treatments versus other
treatments or blank control （control group）. The search period was from the establishment of each database to November 19， 2025.
After literature screening， data extraction， and quality assessment， a meta-analysis was performed using RevMan 5.4 software.
RESULTS A total of 23 studies were included， involving 2 014 patients. Meta-analysis results showed that the effective rate in the
experimental group was significantly higher than that in the control group， the overall incidence and moderate-to-severe incidence
of radiotherapy- and chemotherapy-related intestinal dysfunction， quality of life scores， and interleukin-6 levels in the experimental
group were significantly lower than those in the control group （P＜0.05）. However， no statistically significant differences were
observed between the two groups in terms of Karnofsky Performance Status score improvement rate and tumor necrosis factor-α
levels （P＞0.05）. The results of subgroup analysis based on different medications in the control group showed that， when used for
treatment， regardless of whether patients in the control group received blank control or positive control， the efficacy in the
experimental group was significantly higher than that in the control group （P＜0.05）. When used for prevention， compared with
patients who received blank control in the control group， the overall incidence and the incidence of moderate-to-severe
radiotherapy- and chemotherapy-related intestinal dysfunction in the experimental group were significantly reduced （P＜0.05）. No
statistically significant difference was found in the overall incidence or incidences of moderate-to-severe radiotherapy- and
chemotherapy-related intestinal dysfunction with positive control between the two groups （P＞0.05）. CONCLUSIONS Compound
glutamine enteric-coated capsules can effectively treat and prevent radiotherapy- and chemotherapy-related intestinal dysfunction in
patients with malignant tumors， improve patients’ quality of
Δ 基金项目 四川省科技计划项目（No. 2023NSFSC1696） life， and alleviate inflammatory responses.
＊第一作者 主管药师。研究方向：药物不良反应。E-mail：cyx_ KEYWORDS
01yg3@163.com Compound glutamine enteric-coated capsules；
# 通信作者 主管药师，博士。研究方向：循证药学、药物不良反 intestinal dysfunction； malignant tumors； radiotherapy；
应。E-mail：huqiaozhijay@126.com chemotherapy； meta-analysis； efficacy

· 1068 · China Pharmacy 2026 Vol. 37 No. 8 中国药房 2026年第37卷第8期